Home » Stocks » INFI

Infinity Pharmaceuticals, Inc. (INFI)

Stock Price: $2.00 USD 0.19 (10.50%)
Updated November 27, 1:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 128.41M
Revenue (ttm) 1.59M
Net Income (ttm) -41.28M
Shares Out 64.21M
EPS (ttm) -0.71
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $2.00
Previous Close $1.81
Change ($) 0.19
Change (%) 10.50%
Day's Open 1.81
Day's Range 1.80 - 2.01
Day's Volume 437,303
52-Week Range 0.60 - 2.17

More Stats

Market Cap 128.41M
Enterprise Value 88.69M
Earnings Date (est) Mar 18, 2021
Ex-Dividend Date n/a
Shares Outstanding 64.21M
Float 61.89M
EPS (basic) -0.71
EPS (diluted) -0.71
FCF / Share -0.61
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 183,080
Short Ratio 0.29
Short % of Float 0.30%
Beta 1.81
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 80.66
PB Ratio 8.03
Revenue 1.59M
Operating Income -39.82M
Net Income -41.28M
Free Cash Flow -36.92M
Net Cash 39.73M
Net Cash / Share 0.62
Gross Margin -1,972.03%
Operating Margin -2,501.13%
Profit Margin -2,592.70%
FCF Margin -2,318.78%
ROA -46.92%
ROE -1,839.35%
ROIC -222.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (5)

Buy 3
Overweight 0
Hold 1
Underweight 0
Sell 1

Analyst Consensus: Overweight

Price Target

(31.00% upside)
Current: $2.00
Target: 2.62
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-86.23%269.1%-67.95%-82.83%-33.9%---49.22%30.06%-
Gross Profit3.0522.156.0018.72109165-47.1192.7771.33
Operating Income-45.66-11.93-36.45-30.89-127-7.92-128-52.81-38.53-48.97
Net Income-47.06-11.25-41.83-30.10-128-17.42-127-53.96-40.04-48.98
Shares Outstanding56.9855.4150.5649.6149.0848.5647.9431.7126.6226.32
Earnings Per Share-0.83-0.20-0.83-0.61-2.62-0.36-2.64-1.70-1.50-1.86
Operating Cash Flow-41.53-4.71-36.71-154-83.65118-114-80.14-33.11-26.59
Capital Expenditures-2.33-0.711.48-6.43-1.36-1.75-1.30-1.54-1.95
Free Cash Flow-43.86-4.71-36.00-153-90.08116-116-81.44-34.65-28.53
Cash & Equivalents42.7658.5957.6193.22245334215327116101
Total Debt1.93-6.0019.5920.01---37.55-
Net Cash / Debt40.8358.5951.6173.6322533421532778.85101
Book Value7.7352.4647.7382.4598.5620920131015.4349.48
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Infinity Pharmaceuticals, Inc.
Country United States
Employees 25
CEO Adelene Q. Perkins

Stock Information

Ticker Symbol INFI
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: INFI


Infinity Pharmaceuticals, a biopharmaceutical company, focuses on developing novel medicines for people with cancer. It offers IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the enzyme phosphoinositide-3-kinase-gamma Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib, as well as duvelisib program for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol-Myers Squibb Company. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.